Prospective cost analysis from the provider's perspective: pharmaco-economic results from AGO-WSG intergroup adjuvant EC -> DOC trial vs. CMF in nodal-positive breast cancer and its reimbursement
Dokumenttyp:
Meeting Abstract
Autor(en):
Jacobs, VR; Braun, M; Harbeck, N; Wagenpfeil, S; Sattler, D; Bernard, R; Kuhn, W; Nitz, U; Ihbe-Heffinger, A